홍민희 (연세대학교 의과대학)님 | 한빛사연구자 > 한빛사

연세대학교 의과대학

종양의학

최종업데이트 2025.01.31.

4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy
- Cell Rep. Med., Oct 03 2025, S2666-3791(25)00481-1 | https://doi.org/10.1016/j.xcrm.2025.102408
- 2025-10
- 한빛사논문
Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A phase II multi-center trial
- J. Thorac. Oncol., May 09 2025, S1556-0864(25)00713-0 | https://doi.org/10.1016/j.jtho.2025.05.006
- 2025-05
- 의약학
- 한빛사논문
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
- Cell Rep. Med., January 27, 2025 | https://doi.org/10.1016/j.xcrm.2025.101929
- 2025-01
- 한빛사논문
Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial
- JAMA Oncol., Aug 15 2024, | https://doi.org/10.1001/jamaoncol.2024.2640
- 2024-08
- 의약학
- 한빛사논문
A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
- Clin. Cancer Res., Mar 08 2024, | https://doi.org/10.1158/1078-0432.CCR-23-3249
- 2024-03
- 의약학
- 한빛사논문
YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer
- Clin. Cancer Res., Published Online First : January 22, 2019 | DOI: 10.1158/1078-0432.CCR-18-2906
- 2019-01
- 의약학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기